Details of the Drug Combination

General Information of Drug Combination (ID: DC47MUB)

Drug Combination Name

Cisatracurium Crotamiton

Indication

Disease Entry	Status	REF
Chronic myelogenous leukemia	Investigative	[1]

Component Drugs

Cisatracurium DMUZPJ5

Crotamiton DM2TUCU

Small molecular drug

2D MOL

3D MOL is unavailable

3D MOL

High-throughput Screening Result

Testing Cell Line: KBM-7

Zero Interaction Potency (ZIP) Score: 0.1

Bliss Independence Score: 0.1

Loewe Additivity Score: 12.01

LHighest Single Agent (HSA) Score: 12.03

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Cisatracurium

Disease Entry	ICD 11	Status	REF
Muscle spasm	MB47.3	Approved	[2]

Cisatracurium Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Cholinergic receptor unspecific (CHR)	TTUPDWN	NOUNIPROTAC	Antagonist	[3]
Neuronal acetylcholine receptor alpha-2 (CHRNA2)	TTF4E0J	ACHA2_HUMAN	Antagonist	[4]
------------------------------------------------------------------------------------

Indication(s) of Crotamiton

Disease Entry	ICD 11	Status	REF
Pruritus	EC90	Approved	[2]

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92.
4	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.